Home › Autoimmune Diseases › NCT04119713
Autoimmunity After Checkpoint Blockade
Mechanisms of Immunotoxicology in Cancer Patients
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * A diagnosis of cancer and prescription for a checkpoint inhibitor Exclusion Criteria: * Any subjects not willing or able to give consent * Children under the age of 18 * A history of transplant
About the study
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 600 · Started: Feb 24, 2020
Contact the study team
- Kyra J Sacksith · Phone: 215-898-9339
Official record on ClinicalTrials.gov — NCT04119713
Locations in the U.S.
| Pennsylvania | University of Pennsylvania - Abramson Cancer Center, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.